drugset / Trial / NCT01667926

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

NCT01667926 ↗

Completed 37 enrolled Massachusetts General Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.

Timeline

Start
2013-01
Primary completion
2015-10
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule — Intravenous